Advertisements


Entana Pharmaceuticals Releases Study Results of Hepatitis Treatment in Japanese Patients

Japan has one of the highest rates of hepatitis C in the industrialized worldRelated Stocks: ENTA, ABBV,.....»»

Category: worldSource: nytJan 11th, 2017

Novartis Buys Selexys on Favorable Phase II Data on SelG1

Novartis (NVS) acquired Selexys Pharmaceuticals following the receipt of results from the phase II SUSTAIN study for the treatment of patients with SCD. Swiss drug maker Novartis AG NVS announced that it has acquired Selexys Pharmaceuticals Cor.....»»

Category: topSource: zacksNov 22nd, 2016

AbbVie (ABBV) HCV Combination Drug Positive in Phase IIIb

AbbVie Inc. (ABBV) announced positive results from the phase IIIb study, Garnet, on a combination of its hepatitis drugs Viekirax and Exviera for the treatment of patients with hepatitis C virus (HCV) infection without liver cirrhosis. AbbVie I.....»»

Category: topSource: zacksSep 26th, 2016

Pfizer"s Humira Biosimilar Meets Primary Endpoint in Study

Pfizer, Inc. (PFE) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar of Humira approved for the treatment of patients with rheumatoid arthritis. .....»»

Category: topSource: zacksJan 6th, 2017

Triad firm reports positive results for study of diabetes treatment

High Point-based biopharmaceutical company vTv Therapeutics Inc. announced that it has completed a successful phase 2 study that evaluated its oral therapy used to treat Type 2 diabetes patients. The 12-week study conducted across 30 centers in the U.S. .....»»

Category: topSource: bizjournalsDec 16th, 2016

Cambridge gene therapy firm Voyager gets positive results on Parkinson"s treatment

A Parkinson’s treatment developed by Cambridge gene therapy firm Voyager Therapeutics helped patients improve motor function in a small, early-stage study, the company said Wednesday. Voyager (Nasdaq: VYGR), part of a new wave of gene editing firms in .....»»

Category: topSource: bizjournalsDec 7th, 2016

Pfizer Offers Positive Phase III Data on Pediatric Epilesy Drug

Pfizer Inc. (PFE) announced positive top-line results from a phase III study evaluating its marketed drug, Lyrica (pregabalin), as adjunctive therapy for the treatment of pediatric patients suffering from epilepsy with partial-onset seizures. P.....»»

Category: topSource: zacksDec 2nd, 2016

Testing of Treatment for Cystic Fibrosis Patients Begins

Results of study will be released in the —nd quarter of —…–7Related Stocks: GLPG, ABBV, VRTX,.....»»

Category: blogSource: gurufocusNov 29th, 2016

Adamas (ADMS) Parkinson"s Disease Drug Positive in Phase III

Adamas (ADMS) presented data from the phase III EASE LID 3 study on ADS-5102 for the treatment of levodopa-induced dyskinesia in Parkinson's disease patients. Adamas Pharmaceuticals, Inc. ADMS announced positive data from the phase III study &n.....»»

Category: topSource: zacksSep 21st, 2016

Why Aeri Pharma Won So Big on a Single Trial

Shares of Aeri Pharmaceuticals skyrocketed early Thursday after the company issued positive results on its intraocular pressure (IOP) treatment in patients with glaucoma......»»

Category: blogSource: 247wallstSep 15th, 2016

AcelRx Stock Jumps 20% After Positive Results From Its Trial On ARX-04

AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) disclosed that its investigational product candidate ARX-04 provided solid tolerance level in an open-label Phase three trial for post operative acute pain treatment. This included elderly patients, as well as, or.....»»

Category: earningsSource: benzingaSep 15th, 2016

Aerie Pharma shares jump more than 60% on eye-drug study results

Aerie Pharmaceuticals Inc. shares skyrocketed in the extended session Wednesday after the drug discovery company's treatment for lowering fluid pressure inside the eyeball yielded promising results. Aerie shares jumped 61% to $34 on heavy volume. In a la.....»»

Category: topSource: marketwatchSep 14th, 2016

Lexicon Pharmaceuticals, Sanofi Collab Sotagliflozin Outshines in Phase 3 Diabetes Trial

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stock jumped as high as 24.89% during the early trading hours today, after the company reported the results from its pivotal inTandem1 Phase 3 trial of Sotagliflozin, which is a treatment for diabetes. The study.....»»

Category: topSource: bidnessetcSep 9th, 2016

Lexicon Pharmaceuticals, Inc, Sanofi SA Collab Sotagliflozin Outshines in Phase 3 Diabetes Trial

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stock jumped as high as 24.89% during the early trading hours today, after the company reported the results from its pivotal inTandem1 Phase 3 trial of Sotagliflozin, which is a treatment for diabetes. The study.....»»

Category: topSource: bidnessetcSep 9th, 2016

CoLucid Hits 52 Week High on Positive Data on Migraine Drug

CoLucid (CLCD) announced positive results from a phase III study, SAMURAI, on lasmiditan for the acute treatment of migraine in adults, with or without aura. Shares of CoLucid Pharmaceuticals, Inc. CLCD have been riding high after the company a.....»»

Category: topSource: zacksSep 7th, 2016

Verastem"s CEO Talks DYNAMO Study, The Competitive Landscape And Pitch To Investors

Verastem Inc (NASDAQ: VSTM) is a biopharmaceutical company that focuses on discovering and developing therapies for the treatment of patients with cancer......»»

Category: blogSource: benzingaJan 19th, 2017

This Could Very Well Be the Greatest Drug Advancement in a Decade

Is new hope on the horizon for Alzheimer's disease patients? This drug's initial trial results suggest a new treatment could be coming......»»

Category: topSource: foxnewsJan 9th, 2017

Inotek shares crater 65% after disappointing results from trial of glaucoma treatment

Shares of biotech Inotek Pharmaceuticals Corp. slumped about 66% in premarket trade Tuesday, after the company said a late-stage tri.....»»

Category: topSource: marketwatchJan 3rd, 2017

Lexington-based Inotek sees shares nosedive on glaucoma trial flop

Shares of Lexington-based Inotek Pharmaceuticals plummeted Tuesday morning after the biotech announced that its lead drug candidate, a treatment for glaucoma, had failed in a Phase 3 study. Inotek (Nasdaq: ITEK) said that the drug, an eyedrop called t.....»»

Category: topSource: bizjournalsJan 3rd, 2017

Synergy Pharmaceuticals Inc (SGYP) Moves Closer To Expanding Plecanatide Label

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has provided an update on topline results from a Phase 3 study of its candidate plecanatide. The s.....»»

Category: topSource: insidermonkeyDec 30th, 2016

Galapagos NV Announces Results From Cystic Fibrosis Treatment Study

Researchers observed a decline in sweat chloride concentrationRelated Stocks: GLPG, ABBV, VRTX,.....»»

Category: blogSource: gurufocusDec 27th, 2016